IZOZF - Izotropic Finalizes Engineering and Development Transition to the United States; Establishes Operations in Primary Target Market
(TheNewswire)
VANCOUVER, BC – TheNewswire - August 11,2022 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a MedTech company commercializing IzoView, an advancedthree-dimensional computed tomography (3D CT) breast imaging platform for the more accurate detection and diagnosis of breast cancer , is pleased to report the Company has successfully relocatedIzoView and associated components and completed the transition of allmajor medical device engineering and product development operations toCalifornia.
Further to the Company’s prior announcement ,the move to relocate commercial development of IzoView to Sacramento, CA was made to helpaccelerate testing and optimization of the device as the Companyprepares for its upcoming clinicalstudy and submission for marketauthorization in the U.S.
The technical team, led by Executive Vice President ofProduct Engineering Dr. YounesAchkire , has been testing and calibrating all transferred components of IzoViewonsite while actively pursuing measures tosimplify and streamline the design.
“The decision to transition IzoView R&D andsupply chain efforts to California now creates an environment forfrequent, in-person access to key medical, technical, andmanufacturing partners while better managing supply chain dynamics andoperational oversight,” said Dr. John McGraw, CEO. “Additionalbenefits include mitigation of cross-bordertravel and critical component delivery risks and the opportunity forgreater interaction with our industry peers at US-based hospitals andclinics.”
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
ON BEHALF OF THE BOARD
John McGraw, CEO
Investor Relations Contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible,
to identify such information and statements by usingwords such as "anticipate," "believe,""envision," "estimate," "expect,""intend," "may," "plan,""predict," "project," "target,""potential," "will," "would,""could," "should," "continue,""contemplate" and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risksincluding those related to capital requirements, and uncertaintiesthat are difficult to control or predict, and as such, they may causefuture results of the Company's activity to differ significantly fromthe content and implications of such statements. Forward-LookingStatements are pertinent only as of the date on which they are made,and the Company undertakes no obligation to update or revise anyForward-Looking Statements to reflect new information or theoccurrence of future events or circumstances unless otherwise requiredto do so by law. Neither the Company nor its shareholders, officers,and consultants shall be liable for any action and the results of anyaction taken by any person based on the information contained herein,including, without limitation the purchase or sale of Companysecurities. Nothing in this document should be deemed to be medical orother advice of any kind. All images are for illustrative purposesonly. IzoView is not yet approved for sale.
Copyright (c) 2022 TheNewswire - All rights reserved.